Methods or risk assessment of pml and related apparatus
AssigneeWestfaelische Wilhelms-Universitaet Muenster
InventorsNicholas Schwab, Tilman Schneider-Hohendorf, Heinz Wiendl
Life of this patent
Estimating the term…
Abstract
The invention provides a method of assessing the risk of occurrence of progressive multifocal leukoencephalopathy (PML) in a subject as well as a method of stratifying a subject undergoing VLA-4 blocking agent treatment for suspension of VLA-4 blocking agent treatment. These methods comprise detecting the level of L-selectin (CD62L) and optionally LFA-1 expressing T cells in a sample from the subject.
Claims23
A method of assessing the risk of occurrence of progressive multifocal leukoencephalopathy (PML) in a subject, the method comprising detecting the level of T cells expressing L-selectin (CD62L) in a sample from the subject, wherein a decreased level of CD62L expressing T cells, relative to a threshold value, indicates a risk of occurrence of PML.
A method of stratifying a subject undergoing VLA-4 blocking agent treatment for suspension of the VLA-4 blocking agent treatment, the method comprising detecting the level of T cells expressing at least one of CD62L and LFA-1 in a sample from the subject, wherein a decreased level of CD62L and/or LFA-1 expressing T cells, relative to a threshold value, indicates that the subject is in need of a suspension of VLA-4 blocking agent treatment.
The in vitro use of a capture probe specific for CD62L for at least one of (i) assessing the risk of occurrence of progressive multifocal leukoencephalopathy (PML) in a subject, and (ii) stratifying a subject undergoing VLA-4 blocking agent treatment for suspension of said VLA-4 blocking agent treatment.
The in vitro use of an antibody or a proteinaceous binding molecule with antibody-like functions specific for at least one of CD11A, CD18 and LFA-1 for assessing the risk of occurrence of PML in a subject or stratifying a subject undergoing VLA-4 blocking agent treatment for suspension of said VLA-4 blocking agent treatment.
A VLA-4 blocking agent for use in the treatment of a pathologic inflammatory disease within the CNS and/or an autoimmune disease so as to avoid the occurrence of PML, wherein the use comprises administration of the VLA-4 blocking agent to a subject over a period of time, followed by a discontinuation of the administration for a period of time.
Dependencies are inferred from the claim text.